Third Phase 3 trial in third type of lymphoma to show improvement in overall survival with an ADCETRIS-containing regimen
The HD21 study adds to the body of evidence supporting ADCETRIS as a backbone agent in the treatment of specific lymphomas
Ulcerative Colitis (UC) is a chronic, idiopathic, immune-mediated inflammatory bowel disease (IBD) affecting the large intestine
Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression
Data support the potential of Dupixent as the first new treatment approach in more than a decade and first-ever targeted therapy for COPD
The funds raised from the Whitathon run are utilized to treat underprivileged children suffering from Retinoblastoma
SUPERNOVA is a large Phase III global trial providing the only efficacy data in immunocompromised patients
35,000 doctors from across India pledged their support for the initiative to raise awareness about cardiovascular diseases
225Ac-PSMA-Trillium is an investigational next-generation PSMA-targeted alpha therapy with potential to treat patients with advanced metastatic prostate cancer
Late-breaker Phase 3 STRIDE-10 trial presented as an oral presentation at European Society of Clinical Microbiology and Infectious Diseases
Subscribe To Our Newsletter & Stay Updated
